Document Detail


The effect of orally and vaginally administered misoprostol on inflammatory mediators and cervical ripening during early pregnancy.
MedLine Citation:
PMID:  15964290     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The objective of the present study was to investigate the effect of vaginally and orally administered misoprostol on the local cervical inflammatory response. METHODS: Healthy women with a normal intrauterine pregnancy between 8 and 12 weeks of gestation presenting for an elective termination of pregnancy by vacuum aspiration were recruited into a cohort study with a control and a treatment group. In the treatment group, the women were randomized to misoprostol, 400 mug, given either orally or vaginally 3 h before surgery. Immunohistochemistry staining of CD45, CD68, MMP 8, MMP 9, TIMP 1 and TIMP 2 were assessed in cervical biopsies obtained directly prior to mechanical cervical dilatation and vacuum aspiration. RESULTS: In the treatment group, there was a greater amount of CD45-positive cells in the subepithelium region of the cervix compared to the control group. The staining of CD68 was similar in both groups. The immunostaining of MMP 8 and MMP 9 was greater in the treatment group, while the expression of TIMP 1 and TIMP 2 did not differ between control and treatment groups. CONCLUSIONS: Compared to untreated controls, treatment with misoprostol was associated with a greater expression of inflammatory cells. It could be hypothesized that administration of misoprostol mimics the cervical ripening at term pregnancy by a possible influx and activation of inflammatory cells, which increases MMP 8 and MMP 9 and thereby leads to the degradation of collagen and cervical softening.
Authors:
Annette Aronsson; Ann-Kristin Ulfgren; Berit Ståbi; Anneli Stavreus-Evers; Kristina Gemzell-Danielsson
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Contraception     Volume:  72     ISSN:  0010-7824     ISO Abbreviation:  Contraception     Publication Date:  2005 Jul 
Date Detail:
Created Date:  2005-06-20     Completed Date:  2005-11-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0234361     Medline TA:  Contraception     Country:  United States    
Other Details:
Languages:  eng     Pagination:  33-9     Citation Subset:  IM    
Affiliation:
Department of Woman and Child Health, Division for Obstetrics and Gynecology, Karolinska Institute, S-171 76 Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abortifacient Agents, Nonsteroidal / administration & dosage*
Abortion, Induced
Administration, Intravaginal
Administration, Oral
Adult
Antigens, CD / analysis
Antigens, CD45 / analysis
Antigens, Differentiation, Myelomonocytic / analysis
Cervical Ripening / drug effects*
Female
Gestational Age*
Humans
Immunohistochemistry
Inflammation*
Matrix Metalloproteinase 8 / analysis
Matrix Metalloproteinase 9 / analysis
Misoprostol / administration & dosage*
Pregnancy
Tissue Inhibitor of Metalloproteinase-1 / analysis
Tissue Inhibitor of Metalloproteinase-2 / analysis
Vacuum Curettage
Chemical
Reg. No./Substance:
0/Abortifacient Agents, Nonsteroidal; 0/Antigens, CD; 0/Antigens, Differentiation, Myelomonocytic; 0/CD68 antigen, human; 0/Tissue Inhibitor of Metalloproteinase-1; 127497-59-0/Tissue Inhibitor of Metalloproteinase-2; 59122-46-2/Misoprostol; EC 3.1.3.48/Antigens, CD45; EC 3.4.24.34/Matrix Metalloproteinase 8; EC 3.4.24.35/Matrix Metalloproteinase 9

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of gemeprost and vaginal misoprostol in first trimester mifepristone-induced abortion.
Next Document:  Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three differen...